FDA's ANDA Approvals
Generic drug approvals and tentative approvals in mid- and late March.
You may also be interested in...
Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.
The IGBA has called for a “streamlined” global biosimilar development and registration process, with a new policy paper highlighting the limited value of comparative efficacy clinical data at the same time as it urges renewed efforts on educating healthcare professionals.
Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.